losartan has been researched along with Hyperuricemia in 35 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Hyperuricemia: Excessive URIC ACID or urate in blood as defined by its solubility in plasma at 37 degrees C; greater than 0.42mmol per liter (7.0mg/dL) in men or 0.36mmol per liter (6.0mg/dL) in women. This condition is caused by overproduction of uric acid or impaired renal clearance. Hyperuricemia can be acquired, drug-induced or genetically determined (LESCH-NYHAN SYNDROME). It is associated with HYPERTENSION and GOUT.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Losartan may be an effective agent for treatment of hyperuricemia and PTE in Han Chinese patients after kidney transplantation." | 9.14 | Efficacy and safety of losartan in treatment of hyperuricemia and posttransplantation erythrocytosis: results of a prospective, open, randomized, case-control study. ( Chen, J; Cheng, M; Ding, X; Han, F; Le, Y; Xu, L; Zhang, L; Zhu, X, 2009) |
| "Although allopurinol has been available for approximately 50 years, hyperuricemia and its sequelae are not only prevalent, but the incidence and costs associated with this disorder continue to increase." | 8.82 | Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. ( Bomalaski, JS; Clark, MA, 2004) |
| "A MassARRAY approach was used to detect single nucleotide polymorphism (SNP) loci in the URAT1 and CYP2C9 genes (16 and 2 loci, respectively) in 111 patients with hypertension and hyperuricemia taking losartan and in 121 healthy controls." | 8.02 | The impact of an URAT1 polymorphism on the losartan treatment of hypertension and hyperuricemia. ( Fan, Y; Li, Z; Mao, D; Wang, Y; Wu, L; Zhuang, W, 2021) |
| "To explore the effect of urate transporter 1 (URAT1) polymorphisms on the hypertensive patients with hyperuricemia and the uricosuric action of losartan therapy among hypertensive patients with hyperuricemia." | 7.81 | URAT1 gene polymorphisms influence uricosuric action of losartan in hypertensive patients with hyperuricemia. ( Lou, XY; Peng, Y; Qu, J; Qu, Q; Sun, H; Wang, G; Zeng, Y, 2015) |
| "To investigate the mechanisms underlying the therapeutic effects of losartan on hyperuricemia-induced aortic atherosclerosis, in an experimental rabbit model." | 7.81 | Losartan alleviates hyperuricemia-induced atherosclerosis in a rabbit model. ( Ding, Y; Li, N; Miao, P; Zheng, H, 2015) |
| " Overall serum uric acid (UA) concentration increased, whereas in patients with hyperuricemia there was a significant reduction in this value." | 7.78 | Antihypertensive effect of a fixed-dose combination of losartan/hydrochlorothiazide in patients with uncontrolled hypertension: a multicenter study. ( Akaba, K; Endo, S; Fukui, A; Gomi, H; Hamaguchi, A; Hanaoka, K; Hara, Y; Hasegawa, T; Hayakawa, H; Hayashi, F; Hikida, M; Hirano, K; Horiguchi, M; Hosoya, M; Hosoya, T; Ichida, K; Ikeda, M; Imai, T; Ishii, T; Ishikawa, H; Ishikawa, M; Kameda, C; Kanai, T; Kasai, T; Kawamura, T; Kobayashi, A; Kobayashi, H; Kurashige, M; Kuriyama, S; Kusama, Y; Maezawa, H; Maezawa, Y; Maruyama, Y; Matsuda, H; Matsuo, N; Matsuo, T; Miura, Y; Miyajima, M; Miyakawa, M; Miyazaki, Y; Mizuguchi, M; Morita, T; Nakao, M; Nokano, H; Ogura, M; Ohkido, I; Ohno, I; Ohtsuka, Y; Okada, K; Okamoto, H; Okonogi, H; Saikawa, H; Saito, H; Sekiguchi, C; Soejima, M; Suetsugu, Y; Sugano, N; Suzuki, T; Takahashi, H; Takahashi, Y; Takamizawa, S; Takane, K; Takazoe, K; Tanaka, H; Tanaka, S; Terawaki, H; Tokudome, G; Tomonari, H; Toyoshima, R; Tsuboi, N; Udagawa, T; Ueda, H; Ueda, Y; Uetake, M; Unemura, S; Utsunomiya, M; Utsunomiya, Y; Yamada, T; Yamada, Y; Yamaguchi, Y; Yamamoto, H; Yokoo, T; Yokoyama, K; Yonezawa, H; Yoshida, H; Yoshida, M; Yoshizawa, T, 2012) |
| "Serum uric acid (SUA) is activated in catabolic, hypoxic, and inflammatory conditions characteristic of heart failure (HF) and is a source of reactive oxygen species." | 5.69 | High- versus low-dose losartan and uric acid: An analysis from HEAAL. ( Ferreira, JP; Kiernan, MS; Konstam, MA; Zannad, F, 2023) |
| "We conducted a quasi-experimental, validation study in which patients with primary, uncomplicated hypertension received open-label, fixed combination therapy with amlodipine/losartan 5/50 mg or 5/100 mg according to their baseline blood pressure (BP)." | 5.17 | Echocardiographic changes and treatment goal rates after a 6-month combined treatment with amlodipine and losartan: a validation study in Andean countries (METAL study). ( Pérez Carreño, JG; Romero, JD; Villar Centeno, JC, 2013) |
| "The precise relationship of Hyperuricemia found in hypertensive patients is still obscure; this study is a urinary uric acid lowering intervention with Losartan in hypertensive patients induced by Thiazide diuretics." | 5.15 | To study the efficacy of Losartan on urinary uric acid excretion in Thiazide induced hyperuricemic and hypertensive patients. ( Islam, F; Jamali, SN; Khan, M; Khan, RA; Laghari, J, 2011) |
| "Losartan may be an effective agent for treatment of hyperuricemia and PTE in Han Chinese patients after kidney transplantation." | 5.14 | Efficacy and safety of losartan in treatment of hyperuricemia and posttransplantation erythrocytosis: results of a prospective, open, randomized, case-control study. ( Chen, J; Cheng, M; Ding, X; Han, F; Le, Y; Xu, L; Zhang, L; Zhu, X, 2009) |
| "A combination of fenofibrate or losartan with anti-hyperuricaemic agents is a good option for the treatment of gout patients with hypertriglyceridaemia and/or hypertension, though the additional hypouricaemic effect may be modest." | 5.10 | Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism. ( Fukuchi, M; Ka, T; Moriwaki, Y; Takahashi, S; Tsutsumi, Z; Yamamoto, T, 2003) |
| "Recently, much attention of medical professionals is directed to correlations between hyperuricemia, arterial hypertension, metabolic syndrome and renal affection because of the evidence that elevated blood level of uric acid raises the risk of cardiovascular complications not only in arterial hypertension and metabolic syndrome but also in diabetes mellitus type 2, coronary heart disease, congestive heart failure and renal dysfunction." | 4.87 | [Lozartan potential in hyperuricemia correction]. ( , 2011) |
| "Although allopurinol has been available for approximately 50 years, hyperuricemia and its sequelae are not only prevalent, but the incidence and costs associated with this disorder continue to increase." | 4.82 | Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase. ( Bomalaski, JS; Clark, MA, 2004) |
| "A MassARRAY approach was used to detect single nucleotide polymorphism (SNP) loci in the URAT1 and CYP2C9 genes (16 and 2 loci, respectively) in 111 patients with hypertension and hyperuricemia taking losartan and in 121 healthy controls." | 4.02 | The impact of an URAT1 polymorphism on the losartan treatment of hypertension and hyperuricemia. ( Fan, Y; Li, Z; Mao, D; Wang, Y; Wu, L; Zhuang, W, 2021) |
| "Hyperuricemia and angiotensin II (Ang II) may have a pathogenetic role in the development of hypertension and atherosclerosis as well as cardiovascular disease (CVD) and its prognosis." | 3.85 | Uric acid stimulates proliferative pathways in vascular smooth muscle cells through the activation of p38 MAPK, p44/42 MAPK and PDGFRβ. ( Çetin, A; Kırça, M; Oğuz, N; Uzuner, F; Yeşilkaya, A, 2017) |
| "To explore the effect of urate transporter 1 (URAT1) polymorphisms on the hypertensive patients with hyperuricemia and the uricosuric action of losartan therapy among hypertensive patients with hyperuricemia." | 3.81 | URAT1 gene polymorphisms influence uricosuric action of losartan in hypertensive patients with hyperuricemia. ( Lou, XY; Peng, Y; Qu, J; Qu, Q; Sun, H; Wang, G; Zeng, Y, 2015) |
| "To investigate the mechanisms underlying the therapeutic effects of losartan on hyperuricemia-induced aortic atherosclerosis, in an experimental rabbit model." | 3.81 | Losartan alleviates hyperuricemia-induced atherosclerosis in a rabbit model. ( Ding, Y; Li, N; Miao, P; Zheng, H, 2015) |
| " In other rats, glucose, insulin, uric acid, and insulin sensitivity index, were determined before and after fructose or lipoic acid plus fructose." | 3.79 | A single oral dose of fructose induces some features of metabolic syndrome in rats: role of oxidative stress. ( Hong, E; Moreno, JA, 2013) |
| " Overall serum uric acid (UA) concentration increased, whereas in patients with hyperuricemia there was a significant reduction in this value." | 3.78 | Antihypertensive effect of a fixed-dose combination of losartan/hydrochlorothiazide in patients with uncontrolled hypertension: a multicenter study. ( Akaba, K; Endo, S; Fukui, A; Gomi, H; Hamaguchi, A; Hanaoka, K; Hara, Y; Hasegawa, T; Hayakawa, H; Hayashi, F; Hikida, M; Hirano, K; Horiguchi, M; Hosoya, M; Hosoya, T; Ichida, K; Ikeda, M; Imai, T; Ishii, T; Ishikawa, H; Ishikawa, M; Kameda, C; Kanai, T; Kasai, T; Kawamura, T; Kobayashi, A; Kobayashi, H; Kurashige, M; Kuriyama, S; Kusama, Y; Maezawa, H; Maezawa, Y; Maruyama, Y; Matsuda, H; Matsuo, N; Matsuo, T; Miura, Y; Miyajima, M; Miyakawa, M; Miyazaki, Y; Mizuguchi, M; Morita, T; Nakao, M; Nokano, H; Ogura, M; Ohkido, I; Ohno, I; Ohtsuka, Y; Okada, K; Okamoto, H; Okonogi, H; Saikawa, H; Saito, H; Sekiguchi, C; Soejima, M; Suetsugu, Y; Sugano, N; Suzuki, T; Takahashi, H; Takahashi, Y; Takamizawa, S; Takane, K; Takazoe, K; Tanaka, H; Tanaka, S; Terawaki, H; Tokudome, G; Tomonari, H; Toyoshima, R; Tsuboi, N; Udagawa, T; Ueda, H; Ueda, Y; Uetake, M; Unemura, S; Utsunomiya, M; Utsunomiya, Y; Yamada, T; Yamada, Y; Yamaguchi, Y; Yamamoto, H; Yokoo, T; Yokoyama, K; Yonezawa, H; Yoshida, H; Yoshida, M; Yoshizawa, T, 2012) |
| "Losartan generated a lower incidence than angiotensin-converting enzyme inhibitors of reported dry cough (risk ratio 0." | 2.52 | Losartan treatment for hypertensive patients with hyperuricaemia in Chinese population: a meta-analysis. ( Fan, Y; Lang, Y; Wang, S; Wei, F, 2015) |
| "Gout is increasing worldwide." | 2.49 | Hypertension, its treatment, hyperuricaemia and gout. ( Gibson, TJ, 2013) |
| "Thus, the treatment of hypertension and hyperlipidemia associated with hyperuricemia is also important." | 2.44 | [Other antihyperuricemic agents]. ( Hisatome, I; Igawa, O; Ogino, K, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 14 (40.00) | 29.6817 |
| 2010's | 15 (42.86) | 24.3611 |
| 2020's | 6 (17.14) | 2.80 |
| Authors | Studies |
|---|---|
| Wu, L | 1 |
| Fan, Y | 2 |
| Wang, Y | 1 |
| Li, Z | 1 |
| Mao, D | 1 |
| Zhuang, W | 1 |
| Ferreira, JP | 1 |
| Zannad, F | 1 |
| Kiernan, MS | 1 |
| Konstam, MA | 1 |
| Saad, M | 1 |
| Castilla-Ojo, N | 1 |
| Turkson-Ocran, RA | 1 |
| Conlin, PR | 1 |
| Appel, LJ | 1 |
| Miller, ER | 1 |
| Juraschek, SP | 1 |
| Xiao, Y | 1 |
| Miao, Z | 1 |
| Sun, J | 1 |
| Xing, W | 1 |
| Wei, Y | 1 |
| Bai, J | 1 |
| Ye, H | 1 |
| Si, Y | 1 |
| Cai, L | 1 |
| Kim, HS | 1 |
| Kim, H | 1 |
| Lee, SH | 1 |
| Kim, JH | 1 |
| Nishimura, H | 1 |
| Shintani, M | 1 |
| Maeda, K | 1 |
| Otoshi, K | 1 |
| Fukuda, M | 1 |
| Okuda, J | 1 |
| Nishi, S | 1 |
| Ohashi, S | 1 |
| Kato, S | 1 |
| Baba, Y | 1 |
| Pérez Carreño, JG | 1 |
| Romero, JD | 1 |
| Villar Centeno, JC | 1 |
| Yu, S | 1 |
| Ren, Q | 1 |
| Wu, W | 1 |
| Wei, F | 1 |
| Lang, Y | 1 |
| Wang, S | 1 |
| Sun, H | 1 |
| Qu, Q | 1 |
| Qu, J | 1 |
| Lou, XY | 1 |
| Peng, Y | 1 |
| Zeng, Y | 1 |
| Wang, G | 1 |
| Zheng, H | 1 |
| Li, N | 1 |
| Ding, Y | 1 |
| Miao, P | 1 |
| Kırça, M | 1 |
| Oğuz, N | 1 |
| Çetin, A | 1 |
| Uzuner, F | 1 |
| Yeşilkaya, A | 1 |
| Hamada, T | 1 |
| Ichida, K | 2 |
| Hosoyamada, M | 1 |
| Mizuta, E | 1 |
| Yanagihara, K | 1 |
| Sonoyama, K | 1 |
| Sugihara, S | 1 |
| Igawa, O | 2 |
| Hosoya, T | 2 |
| Ohtahara, A | 1 |
| Shigamasa, C | 1 |
| Yamamoto, Y | 1 |
| Ninomiya, H | 1 |
| Hisatome, I | 2 |
| Zhu, X | 1 |
| Chen, J | 1 |
| Han, F | 1 |
| Cheng, M | 1 |
| Xu, L | 1 |
| Zhang, L | 1 |
| Ding, X | 1 |
| Le, Y | 1 |
| Doria, A | 1 |
| Krolewski, AS | 1 |
| Dawson, J | 1 |
| Walters, M | 1 |
| Perez-Ruiz, F | 1 |
| Herrero-Beites, AM | 1 |
| Carmona, L | 1 |
| Ohshiro, K | 1 |
| Sakima, A | 1 |
| Nakada, S | 1 |
| Kohagura, K | 1 |
| Yamazato, M | 1 |
| Tana, T | 1 |
| Ohya, Y | 1 |
| Khan, M | 1 |
| Khan, RA | 1 |
| Islam, F | 1 |
| Laghari, J | 1 |
| Jamali, SN | 1 |
| Kuriyama, S | 1 |
| Ohno, I | 1 |
| Kawamura, T | 1 |
| Ogura, M | 1 |
| Ikeda, M | 1 |
| Ishikawa, M | 1 |
| Hayashi, F | 1 |
| Kanai, T | 1 |
| Tomonari, H | 1 |
| Soejima, M | 1 |
| Akaba, K | 1 |
| Tokudome, G | 1 |
| Endo, S | 1 |
| Fukui, A | 1 |
| Gomi, H | 1 |
| Hamaguchi, A | 1 |
| Hanaoka, K | 1 |
| Hara, Y | 2 |
| Hasegawa, T | 1 |
| Hayakawa, H | 1 |
| Hikida, M | 1 |
| Hirano, K | 1 |
| Horiguchi, M | 1 |
| Hosoya, M | 1 |
| Imai, T | 1 |
| Ishii, T | 1 |
| Ishikawa, H | 1 |
| Kameda, C | 1 |
| Kasai, T | 1 |
| Kobayashi, A | 1 |
| Kobayashi, H | 1 |
| Kurashige, M | 1 |
| Kusama, Y | 1 |
| Maezawa, H | 1 |
| Maezawa, Y | 1 |
| Maruyama, Y | 1 |
| Matsuda, H | 1 |
| Matsuo, N | 1 |
| Matsuo, T | 1 |
| Miura, Y | 1 |
| Miyajima, M | 1 |
| Miyakawa, M | 1 |
| Miyazaki, Y | 1 |
| Mizuguchi, M | 1 |
| Nakao, M | 1 |
| Nokano, H | 1 |
| Ohkido, I | 1 |
| Ohtsuka, Y | 1 |
| Okada, K | 1 |
| Okamoto, H | 1 |
| Okonogi, H | 1 |
| Saikawa, H | 1 |
| Saito, H | 1 |
| Sekiguchi, C | 1 |
| Suetsugu, Y | 1 |
| Sugano, N | 1 |
| Suzuki, T | 2 |
| Takahashi, H | 1 |
| Takahashi, Y | 1 |
| Takamizawa, S | 1 |
| Takane, K | 1 |
| Morita, T | 1 |
| Takazoe, K | 1 |
| Tanaka, H | 1 |
| Tanaka, S | 1 |
| Terawaki, H | 1 |
| Toyoshima, R | 1 |
| Tsuboi, N | 1 |
| Udagawa, T | 1 |
| Ueda, H | 1 |
| Ueda, Y | 1 |
| Uetake, M | 1 |
| Unemura, S | 1 |
| Utsunomiya, M | 1 |
| Utsunomiya, Y | 1 |
| Yamada, T | 1 |
| Yamada, Y | 1 |
| Yamaguchi, Y | 1 |
| Yamamoto, H | 1 |
| Yokoo, T | 1 |
| Yokoyama, K | 1 |
| Yonezawa, H | 1 |
| Yoshida, H | 1 |
| Yoshida, M | 1 |
| Yoshizawa, T | 1 |
| Moreno, JA | 1 |
| Hong, E | 1 |
| Gibson, TJ | 1 |
| Bardin, T | 1 |
| Takahashi, S | 1 |
| Moriwaki, Y | 1 |
| Yamamoto, T | 1 |
| Tsutsumi, Z | 1 |
| Ka, T | 1 |
| Fukuchi, M | 1 |
| Sidorenko, BA | 1 |
| Ugriumova, MO | 1 |
| Alderman, M | 2 |
| Aiyer, KJ | 1 |
| Bomalaski, JS | 1 |
| Clark, MA | 1 |
| Tatsuno, I | 1 |
| Redfern, JS | 1 |
| Høieggen, A | 1 |
| Os, I | 1 |
| Kjeldsen, SE | 1 |
| Dang, A | 1 |
| Zhang, Y | 1 |
| Liu, G | 1 |
| Chen, G | 1 |
| Song, W | 1 |
| Wang, B | 1 |
| Rayner, BL | 1 |
| Trinder, YA | 1 |
| Baines, D | 1 |
| Isaacs, S | 1 |
| Opie, LH | 1 |
| Ogino, K | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Allopurinol in the Treatment of Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Treated by Either PCI or CABG: Pilot Study[NCT03700645] | Phase 4 | 100 participants (Anticipated) | Interventional | 2018-12-01 | Not yet recruiting | ||
| Losartan and Uric Acid Metabolism in Children With Proteinuric Nephropathies: a Cross-over Randomized Clinical Trail[NCT05402397] | Phase 4 | 40 participants (Anticipated) | Interventional | 2022-07-01 | Recruiting | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
11 reviews available for losartan and Hyperuricemia
| Article | Year |
|---|---|
Losartan treatment for hypertensive patients with hyperuricaemia in Chinese population: a meta-analysis.
Topics: Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Antihypertensive | 2015 |
Uric acid and xanthine oxidase: future therapeutic targets in the prevention of cardiovascular disease?
Topics: Cardiovascular Diseases; Humans; Hyperuricemia; Losartan; Risk Factors; Uric Acid; Xanthine Oxidase | 2006 |
[Lozartan potential in hyperuricemia correction].
Topics: Antihypertensive Agents; Humans; Hypertension; Hyperuricemia; Losartan; Metabolic Syndrome; Uric Aci | 2011 |
Hypertension, its treatment, hyperuricaemia and gout.
Topics: Antihypertensive Agents; Blood Pressure; Diuretics; Female; Gout; Humans; Hypertension; Hyperuricemi | 2013 |
[New perspectives of the use of angiotensin II receptor blocker].
Topics: Angiotensin II; Angiotensin Receptor Antagonists; Antihypertensive Agents; Atenolol; Diabetes Mellit | 2003 |
Uric acid: role in cardiovascular disease and effects of losartan.
Topics: Angiotensin Receptor Antagonists; Antihypertensive Agents; Cardiovascular Diseases; Humans; Hyperuri | 2004 |
Serum uric acid-lowering therapies: where are we heading in management of hyperuricemia and the potential role of uricase.
Topics: Allopurinol; Amlodipine; Clinical Trials as Topic; Enzyme Inhibitors; Febuxostat; Gout; Humans; Hype | 2004 |
[Hyperuricemia in hypertension].
Topics: Animals; Antihypertensive Agents; Arteriosclerosis; Calcium Channel Blockers; Diet, Sodium-Restricte | 2004 |
[Serum uric acid--a cardiovasular risk factor?].
Topics: Angiotensin II Type 1 Receptor Blockers; Cardiovascular Diseases; Clinical Trials as Topic; Humans; | 2004 |
[Uric acid--more deleterious than we thought?].
Topics: Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Cardiovascular Diseases; Female; H | 2005 |
[Other antihyperuricemic agents].
Topics: Antihypertensive Agents; Cardiovascular Diseases; Drug Therapy, Combination; Fenofibrate; Gout; Gout | 2008 |
9 trials available for losartan and Hyperuricemia
| Article | Year |
|---|---|
High- versus low-dose losartan and uric acid: An analysis from HEAAL.
Topics: Heart Failure; Humans; Hyperuricemia; Losartan; Stroke Volume; Uric Acid; Ventricular Function, Left | 2023 |
Effects of the DASH diet and losartan on serum urate among adults with hypertension: Results of a randomized trial.
Topics: Adult; Dietary Approaches To Stop Hypertension; Female; Gout; Humans; Hypertension; Hyperuricemia; L | 2023 |
Which is a better treatment for hypertensive patients with diabetes: a combination of losartan and hydrochlorothiazide or a maximum dose of losartan?
Topics: Aged; Albuminuria; Antihypertensive Agents; Diabetes Mellitus, Type 2; Dose-Response Relationship, D | 2013 |
Echocardiographic changes and treatment goal rates after a 6-month combined treatment with amlodipine and losartan: a validation study in Andean countries (METAL study).
Topics: Aged; Albuminuria; Amlodipine; Antihypertensive Agents; Blood Pressure; Dose-Response Relationship, | 2013 |
Efficacy and safety of losartan in treatment of hyperuricemia and posttransplantation erythrocytosis: results of a prospective, open, randomized, case-control study.
Topics: Adult; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Blood Pressure; Case-Control Studies | 2009 |
To study the efficacy of Losartan on urinary uric acid excretion in Thiazide induced hyperuricemic and hypertensive patients.
Topics: Aged; Humans; Hydrochlorothiazide; Hypertension; Hyperuricemia; Kidney; Losartan; Middle Aged; Sodiu | 2011 |
Effects of combination treatment using anti-hyperuricaemic agents with fenofibrate and/or losartan on uric acid metabolism.
Topics: Adult; Angiotensin Receptor Antagonists; Drug Therapy, Combination; Fenofibrate; Gout Suppressants; | 2003 |
Effects of losartan and irbesartan on serum uric acid in hypertensive patients with hyperuricaemia in Chinese population.
Topics: Angiotensin II Type 1 Receptor Blockers; Asian People; Biphenyl Compounds; Blood Pressure; China; Do | 2006 |
Effect of losartan versus candesartan on uric acid, renal function, and fibrinogen in patients with hypertension and hyperuricemia associated with diuretics.
Topics: Antihypertensive Agents; Benzimidazoles; Biphenyl Compounds; Blood Pressure; Diuretics; Female; Fibr | 2006 |
15 other studies available for losartan and Hyperuricemia
| Article | Year |
|---|---|
The impact of an URAT1 polymorphism on the losartan treatment of hypertension and hyperuricemia.
Topics: Adult; Aged; Antihypertensive Agents; Cytochrome P-450 CYP2C9; Female; Humans; Hypertension; Hyperur | 2021 |
Hyperuricemia and Gout: The Role of Losartan.
Topics: Antihypertensive Agents; Gout; Humans; Hyperuricemia; Losartan | 2023 |
Allisartan Isoproxil Promotes Uric Acid Excretion by Interacting with Intestinal Urate Transporters in Hyperuricemic Zebrafish (Danio rerio).
Topics: Animals; Hyperuricemia; Kidney; Losartan; Uric Acid; Zebrafish | 2023 |
Comparative analysis of the efficacy of angiotensin II receptor blockers for uric acid level change in asymptomatic hyperuricaemia.
Topics: Adult; Aged; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Cohort Stud | 2020 |
Effects of losartan on expression of monocyte chemoattractant protein-1 (MCP-1) in hyperuricemic nephropathy rats.
Topics: Animals; Chemokine CCL2; Dose-Response Relationship, Drug; Hyperuricemia; Kidney; Kidney Diseases; L | 2015 |
URAT1 gene polymorphisms influence uricosuric action of losartan in hypertensive patients with hyperuricemia.
Topics: Aged; Female; Genetic Association Studies; Genotype; Humans; Hypertension; Hyperuricemia; Losartan; | 2015 |
Losartan alleviates hyperuricemia-induced atherosclerosis in a rabbit model.
Topics: Animals; Antihypertensive Agents; Aorta; Atherosclerosis; Blotting, Western; Disease Models, Animal; | 2015 |
Uric acid stimulates proliferative pathways in vascular smooth muscle cells through the activation of p38 MAPK, p44/42 MAPK and PDGFRβ.
Topics: Angiotensin II; Animals; Atherosclerosis; Cardiovascular Diseases; Cell Proliferation; Gene Expressi | 2017 |
Uricosuric action of losartan via the inhibition of urate transporter 1 (URAT 1) in hypertensive patients.
Topics: Administration, Oral; Aged; Angiotensin II Type 1 Receptor Blockers; Benzimidazoles; Biphenyl Compou | 2008 |
Diabetes: Lowering serum uric acid levels to prevent kidney failure.
Topics: Angiotensin II Type 1 Receptor Blockers; Diabetic Nephropathies; Humans; Hyperuricemia; Kidney Failu | 2011 |
A two-stage approach to the treatment of hyperuricemia in gout: the "dirty dish" hypothesis.
Topics: Aged; Cohort Studies; Colchicine; Crystallization; Female; Fenofibrate; Follow-Up Studies; Gout; Gou | 2011 |
Beneficial effect of switching from a combination of angiotensin II receptor blockers other than losartan and thiazides to a fixed dose of losartan/hydrochlorothiazide on uric acid metabolism in hypertensive patients.
Topics: Aged; Angiotensin II Type 1 Receptor Blockers; Antihypertensive Agents; Blood Pressure; Dose-Respons | 2011 |
Antihypertensive effect of a fixed-dose combination of losartan/hydrochlorothiazide in patients with uncontrolled hypertension: a multicenter study.
Topics: Adult; Aged; Antihypertensive Agents; Blood Pressure; Blood Pressure Determination; Creatinine; Drug | 2012 |
A single oral dose of fructose induces some features of metabolic syndrome in rats: role of oxidative stress.
Topics: Administration, Oral; Animals; Blood Glucose; Blood Pressure; Dose-Response Relationship, Drug; Fruc | 2013 |
Fenofibrate and losartan.
Topics: Drug Therapy, Combination; Fenofibrate; Gout Suppressants; Humans; Hypertension; Hyperuricemia; Losa | 2003 |